The sector is dominated by a small group of multinational corporations.
Significant efforts are underway to align U.S. drug prices with lower international rates. Big Pharma
Eli Lilly, Johnson & Johnson, AbbVie, and Roche are among the largest global players. The sector is dominated by a small group
Key drugs driving recent revenue include semaglutide (Ozempic/Wegovy) from Novo Nordisk and various high-cost therapies for chronic conditions. Current Pricing and Regulatory Trends Eli Lilly, Johnson & Johnson, AbbVie, and Roche
A significant portion of these companies is owned by large institutional investors like Blackrock, Vanguard, and State Street, which collectively hold roughly 20% of the industry.
"Big Pharma" refers to the world's largest publicly traded pharmaceutical companies. As of late 2025, the industry is navigating significant regulatory changes, particularly in the United States, where the Trump administration has been pressuring major manufacturers to lower prescription costs through "Most-Favored-Nation" (MFN) pricing. Market Leaders and Ownership